The first domestic cervical cancer vaccine will be approved for market soon!

According to the securities times on July 3, the technical review of the bivalent HPV vaccine jointly declared by Xiamen Wantai Canghai, Xiamen University and Wantai biology has been basically completed, and is currently waiting for on-site verification According to the vaccine listing process, after the products are qualified in the on-site inspection and three batches of inspection, the drug regulatory department will conduct a three in one comprehensive evaluation, and will issue production approval documents to the enterprises for vaccines that are considered safe, effective, authentic and controllable in quality If approved, the bivalent HPV vaccine will be the first domestic cervical cancer vaccine in China, making China the third country with independent supply capacity of cervical cancer vaccine after the United States and the United Kingdom According to the data, Xiamen Wantai Canghai was founded in 2005 It is a wholly-owned subsidiary of Beijing Wantai bio Pharmaceutical Co., Ltd under Yangshengtang It is mainly engaged in vaccine research, production and marketing, and is one of the core businesses of the parent company Wantai bio At present, in addition to the bivalent HPV vaccine, the bivalent vaccine is also in the clinical research ranks of Wantai Canghai vaccine products The vaccine products under research of Wantai Canghai are as follows: Source: the prospectus of Wantai biology recently, its parent company Wantai biology also updated the prospectus of IPO (application draft), which will raise 380 million yuan About 39% of the funds raised will be used for the international project of cervical cancer vaccine quality promotion machine A person in the industry told Sina pharmaceutical that the completion of the review of Wantai Canghai cervical cancer vaccine means that it has high-quality vaccine R & D capability, which will highlight the strength effect of the parent company and help the success in the capital market At present, with the rising willingness of women of appropriate age to vaccinate in China, according to the conservative calculation of vaccination rate, the stock market space of HPV vaccine with 2, 4 and 9 prices is about 1.5 billion yuan, 24.5 billion yuan and 26 billion yuan respectively More research institutions report that the market scale of HPV vaccine in China will exceed 70 billion yuan Recently, according to the latest research published by the World Health Organization in the lancet, there is strong evidence that HPV vaccine can prevent cervical cancer and should be extended to boys and adults Data shows that there are about 130000 new cases of cervical cancer in China every year, accounting for one third of the global new cases, and the market demand for cervical cancer vaccine will increase dramatically in the future In terms of the market sales data of the approved HPV vaccine in China, the sales revenue of GlaxoSmithKline hit a rebound after it was approved to be listed in China In 2017, the sales reached 134 million pounds, an increase of 65% year on year After the approval of MSD's four price jiadaxiu in China in May 2017, the global revenue of the whole cervical cancer vaccine of MSD increased by 6%, reaching a new high of $2.308 billion In the face of huge market demand, more than ten domestic enterprises have been carrying out research projects At present, in addition to the bivalent HPV vaccine jointly declared by Xiamen Wantai Canghai, Xiamen University and Wantai biology, which has basically completed the technical approval work, with reference to the information of "drug clinical trial registration and information publicity platform", Watson biology, Chengdu Biological Products Research Institute, Bowei biology, Shanghai Biological Products Research Institute, nooning biology, Jiangsu Ruike and other enterprises' HPV vaccine products Also in clinical trials.